Brief: Arvinas And Pfizer Announce Interim Data From Phase 1B Trial Of Vepdegestrant In Combination With Palbociclib (Ibrance®) And Plans To Expand Vepdegestrant Development Program

Arvinas

05/12/2023 18:37

Dec 5 (Reuters) - Arvinas Inc  ARVN.O :
    * ARVINAS AND PFIZER ANNOUNCE INTERIM DATA FROM PHASE 1B
TRIAL OF
VEPDEGESTRANT IN COMBINATION WITH PALBOCICLIB (IBRANCE®) AND
PLANS TO EXPAND VEPDEGESTRANT DEVELOPMENT PROGRAM
    * ARVINAS- CO, PFIZER PLAN TO BROADEN DEVELOPMENT OF
VEPDEGESTRANT
TO INCLUDE NEW COMBINATIONS WITH CDK INHIBITORS IN BOTH FIRST- &
SECOND-LINE SETTINGS
    * ARVINAS INC - TOLERABILITY GENERALLY CONSISTENT WITH
PROFILE OF
PALBOCICLIB AND WHAT HAS BEEN OBSERVED IN OTHER CLINICAL TRIALS
OF VEPDEGESTRANT
    * ARVINAS INC - OVERALL RESPONSE RATE OF 42% AND MEDIAN
PROGRESSION-FREE SURVIVAL OF 11.1 MONTHS IN HEAVILY PRE-TREATED
PATIENTS
    * ARVINAS: PLAN TO INITIATE NEW SECOND-LINE PHASE 3 TRIAL OF
VEPDEGESTRANT IN COMBINATION WITH PALBOCICLIB AND POTENTIALLY
OTHER CDK4/6 INHIBITORS
    * ARVINAS INC - PLAN TO INITIATE NEW SECOND-LINE PHASE 3
TRIAL OF
VEPDEGESTRANT IN COMBINATION WITH PALBOCICLIB AND POTENTIALLY
OTHER CDK4/6 INHIBITORS
    * ARVINAS INC: PLAN TO INITIATE A NEW FIRST-LINE PHASE 3
TRIAL OF
VEPDEGESTRANT PLUS PFIZER'S NOVEL CDK4 INHIBITOR (PF-07220060)

Source text for Eikon:  ID:nGNX8TtjDb 
Further company coverage:  ARVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))